This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.

Inclusion Criteria:

• Patients at least 18 years of age at Visit 1
• Drug naïve patients with T2DM diagnosed at least 2 months prior to Visit 1
• HbA1c ≥ 7.0 % and ≤ 10.0% at Visit 1
• Body Mass Index (BMI) in the range of 22-45 kg/m2 at Visit 1

Exclusion Criteria:

• Pregnant or lactating female
• FPG ≥ 270 mg/dL (≥15 mmol/L)

Other protocol-defined inclusion/exclusion criteria may apply